Autopsy report · NCT00949117
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
Cause of deathSlow enrollment
“study not feasible with low accrual. DSMB recommended closure”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 2 months before it stopped.
- 9 participants enrolled.
- Results were posted on the registry 2 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of South Florida
- Sponsor type
- University, hospital or other
- Conditions
- Leukemia; Lymphoma; Malnutrition; Myelodysplastic Syndromes; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes
- Interventions
- Ensure; PediaSure; cyproheptadine hydrochloride
- Participants
- 9
Trials that died the same way
- Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
“DSMB determined, due to higher than expected risk/safety concerns, study should be closed.” - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
“Study was closed to low accrual.” - A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
“The Data Safety Monitoring Board (DSMB) recommended study termination for slow accrual and futility.” - UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
“IRB study closure” - ATG Plus Low-dose PT-Cy for GVHD Prevention
“DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.